Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be Favorable EDINBURGH, United Kingdom , Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced
Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics EDINBURGH, United Kingdom , Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical
Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile Confirmed NuTide:121 Global Phase III Study Recruitment Ongoing EDINBURGH, United Kingdom , Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the final results of the Phase Ib study of
Completed Successful $ 8 0 million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020 EDINBURGH, United Kingdom , Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30,
EDINBURGH, United Kingdom , Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held
EDINBURGH, United Kingdom , Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference .
Abingworth Makes Significant Investment in NuCana’s Recent $80 million Public Offering EDINBURGH, United Kingdom , Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the
Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302) NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a
EDINBURGH, United Kingdom , Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889
EDINBURGH, United Kingdom , Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc , a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares
